Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers.

Molecular Diagnosis & Therapy
Athina PyrpasopoulouSpyros Aslanidis

Abstract

Rituximab is used to deplete B cells and control disease activity, mainly in patients with rheumatoid arthritis (RA) who have not responded to anti-tumor necrosis factor (TNF) therapy. Response rates and time to relapse vary significantly among treated individuals. The objective of this study was to monitor the response of seropositive and seronegative RA patients to rituximab and correlate relapse with B-cell markers in the two groups. Seventeen RA patients (eight seropositive for rheumatoid factor [RF+] and nine seronegative [RF-]) were treated with two cycles of rituximab. After treatment, all patients were re-evaluated at the outpatient clinic, and rituximab was readministered when disease relapse was confirmed by clinical-laboratory measures (Disease Activity Score [DAS]-28). CD20+ cells and CD20 receptor expression levels were estimated at initiation, relapse, and re-evaluation timepoints, and were compared between the two groups. Seropositive patients responded favorably to treatment compared with the seronegative group. The mean time to relapse was 337.5 +/- 127.0 days for the RF+ patients versus 233.3 +/- 59.6 days for the RF- patients (p = 0.043), despite more aggressive concomitant treatment in the seronegative group...Continue Reading

References

Aug 9, 2003·Arthritis and Rheumatism·Geraldine CambridgeAnthony D B Webster
Jul 9, 2004·Scandinavian Journal of Immunology·P SzodorayM Centola
Nov 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Michael E WilliamsRonald P Taylor
Sep 4, 2007·Journal of Clinical Pharmacology·Ferdinand BreedveldBrian E Davies
Sep 28, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·James E Frampton, Lesley J Scott
Oct 5, 2007·Current Rheumatology Reports·Jennifer Kwan-Morley, Daniel Albert
Jun 19, 2008·Arthritis Research & Therapy·Josef S SmolenOswald Wagner
Jul 1, 2008·Current Opinion in Immunology·Ronald P Taylor, Margaret A Lindorfer
Nov 28, 2008·Arthritis and Rheumatism·Arumugam PalanichamyHans-Peter Tony
Feb 25, 2009·British Journal of Haematology·Liuyan JiangMaryalice Stetler-Stevenson

❮ Previous
Next ❯

Citations

Aug 2, 2013·British Journal of Nursing : BJN·Deborah Palmer, Yasser El Mledany
Jun 22, 2012·Clinical Reviews in Allergy & Immunology·Rita A MouraJoão E Fonseca
Aug 3, 2011·Expert Opinion on Biological Therapy·Abdul Khan, David Scott
Sep 9, 2021·Clinical Reviews in Allergy & Immunology·Maria V SokolovaUlrike Steffen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.